Outcomes of unrelated cord blood transplantation in pediatric recipients

We report results of unrelated cord blood transplants (UCBT) in 29 pediatric recipients in one center and the risk factors associated with survival. Median age: 9 years (0.5-20); diagnosis: ALL (9), AML (4), CML (1), HD (3), HLH (1), NHL (3), NBL (2); B-thal (1), FA (1), FEL (1), Krabbe (1), WAS (1), SAA (1); median follow-up: 11 months; conditioning: total body irradiation (TBI)-ablative ( 14), chemotherapy-ablative ( 6) and reduced intensity chemotherapy ( 9); GVHD prophylaxis: MMF/FK506 (18), cyclosporin A (CsA) + steroids +/- MMF (7) or CsA + methotrexate (MTX) (4); median total nucleated cells (TNC): 3.8 x 10(7)/kg (1.1-11); median CD34 +: 2.3 x 10(5)/kg (0.2-9.9); and HLA match: 2 (6/6), 5 (5/6), 22 (4/6). Neutrophil engraftment by cumulative incidence curves 63% (median 28 (95% confidence interval (CI) 18-32)). Probability of greater than or equal tograde II acute graft-versus-host disease (aGVHD) by day + 60 27%, greater than or equal tograde III aGVHD 20% and chronic graft-versus-host disease 3%. Estimated 1-year overall survival ( OS) 46% (95% CI 30-71) and standard risk 60% (95% CI 29-100%). Variables associated with improved survival by multivariate analysis include non-TBI-ablative conditioning (P = 0.024), CD34 + kg (P = 0.038) and gender (P = 0.048). These results suggest that CD34/kg cell dose and non-TBI-ablative conditioning may be important variables influencing OS following UCBT in pediatric recipients. Given the small number of patients, these results should be viewed cautiously.